Please login to the form below
CML
This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.
Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib
Novartis has been at the forefront of CML research for years – significantly changing the prognosis for patients. ... with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP).
Latest news
-
Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial
patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP). ... The US Food and Drug Administration (FDA) has already granted asciminib a fast track designation in CML.
-
Pfizer gets first FDA nod for hedgehog inhibitor in AML
indications such as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
-
Inside the patient-centricity bubble
There has been some egregious behaviour in the industry in terms of drug pricing,” he said referring to the net price of CML drugs, which have tripled over the course of
-
Pfizer’s leukaemia drug Mylotarg backed for use in EU
Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).
-
FDA’s year-end approvals take annual tally to 46
Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... It has become the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation
Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial
Pfizer gets first FDA nod for hedgehog inhibitor in AML
Inside the patient-centricity bubble
FDA’s year-end approvals take annual tally to 46
More from news
Approximately 5 fully matching, plus 49 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
-
Deal Watch January 2017
With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase
-
Deal Watch May 2016
In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and
-
Seismic shifts: Hepatitis C and payers
Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.
-
Deal Watch table for December 2014
Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).
Drug launches to watch in 2019
Deal Watch January 2017
Seismic shifts: Hepatitis C and payers
Deal Watch table for December 2014
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Helen Parfitt joins Research Partnership
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
Helen Parfitt joins Research Partnership
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Spotlight interview: 15 minutes on healthcare advertising
Marie Little, Managing Director, OPEN Health Patient &Brand Communications takes 15 minutes to answer some key questions on healthcare advertising. 1. WHAT IS HEALTHCARE ADVERTISING IN A NUTSHELL? Healthcare advertising follows the same principals
-
Spotlight interview: 15 minutes on patient-centricity in pharma
We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
-
Therapy Watch expands oncology and IBD portfolios
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... US. CML is a rare cancer affecting the white blood
-
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch
expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017. .
-
Research Partnership
new Chronic Myelogenous Leukaemia (CML) study in the US.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
